The landscape of AI-driven business transformation is dominated by companies that often operate behind the scenes, focusing on specialised verticals rather than broad, consumer-facing applications.

These companies utilise vertical AI to tailor solutions specifically for individual sectors, maximising efficiency and strategic insight.

1. Professional Services: Vertical AI is making significant strides in professional services.

For instance, legal tech companies like Harvey and Responsiv leverage AI to expedite legal research and documentation processes, allowing professionals to focus more on strategic aspects of their work.

2. Business Services: Vamstar is enhancing efficiencies in the life sciences sector by optimising procurement processes and improving data analytics for better decision-making in lifescience organisations.

3. Financial Services: In the financial sector, companies like Truewind and Trullion are transforming financial management with AI, automating workflows to ensure precision and efficiency.

These tools not only streamline operations but also provide predictive analytics that can transform underwriting and customer services.

4. Healthcare and Biotech: AI’s role in healthcare is profound, with companies developing solutions that streamline drug development and enhance precision medicine.

For example, Deloitte highlights how AI can optimise clinical trials and advance manufacturing processes in the biopharma sector, potentially speeding up the delivery of new therapies.

5. Retail and E-commerce: Retail giants like Toast and Shopify have successfully integrated AI into their operations, transforming how businesses manage inventory, process payments, and interact with customers.

Their platforms demonstrate how vertical-specific AI can not only support existing business operations but also create new opportunities for growth and customer engagement.

Vertical AI companies, such as Vamstar in the life sciences sector, illustrate the subtlety with which AI can be integrated into industry-specific workflows, enhancing efficiency and profitability without the broad public visibility of consumer-facing AI technologies.

As these specialised AI solutions continue to evolve, they promise to transform industries by addressing specific challenges and maximising operational efficiencies.

Introduction

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has recently published a white paper addressing key challenges in medicine procurement within the EU and UK. This white paper emphasises the need for effective and sustainable procurement practices that can deliver high-quality medicines to patients in appropriate quantities and at the right time.

Background on Tendering Practices

Tendering processes in pharmaceuticals play a crucial role in determining how medicines are procured and distributed. These processes, however, have been plagued by various issues that affect competition and limit access to essential medications. A recent EFPIA survey highlighted seven anomalies in national tendering practices in the EU & UK that harm competition and potentially limit patients’ access to medicines.

EFPIA’s White Paper Overview

EFPIA’s white paper, published on February 10, 2022, presents a sector-specific contribution to the broader debate on the efficacy of the EU procurement rules. It aims to improve not only the formal public procurement procedures but also the informal tendering processes increasingly employed outside the confines of Directive 2014/24/EU.

The Ten Recommendations

1.Transparency in Procurement Processes: Advocates for clearer and more open procedures to enhance fairness.
2. Balancing Cost with Quality: Proposes evaluating tenders based on both price and quality.
3. Long-Term Agreements: Suggests longer contracts to ensure stable supply and predictability for manufacturers.
4. Risk Mitigation Strategies: Recommends measures to prevent drug shortages, including contingency plans.
5. Incentivising Innovation: Encourages mechanisms to reward and promote the development of new treatments.
6. Sustainable Pricing Models: Calls for pricing that reflects the value of medicines while ensuring accessibility.
7. Collaboration with Stakeholders: Stresses the importance of involving all relevant parties in the procurement process.
8. Flexibility in Contracts: Advises adapting contracts as new treatments become available or needs change.
9. Streamlined Administrative Processes: Recommends reducing bureaucracy in the procurement process.
10. Regular Monitoring and Review: Urges ongoing assessment of procurement practices for effectiveness.

Expanded Insights

EFPIA’s recommendations focus on three distinct types of public procurement rules and practices. These include traditional EU public procurement rules, the 2014 Joint Procurement Agreement, and informal tendering processes. The recommendations seek to enhance efficiency, bolster fair competition, and address flaws revealed in market feedback obtained from a survey of tendering practices in 18 countries across the EU and the UK.

Impact on Healthcare and Industry

Implementing these recommendations could lead to more affordable medication prices, fostering accessibility and stimulating growth in the pharmaceutical sector. Furthermore, encouraging innovation could result in the development of new, more effective treatments, significantly improving patient outcomes.

Conclusion

EFPIA’s recommendations offer a roadmap for enhancing medicine procurement practices in the EU and UK, aiming to improve access to quality medicines and foster a more dynamic pharmaceutical sector. While challenges in implementation exist, the potential benefits for healthcare delivery and industry growth are substantial.

In this context, platforms like Vamstar’s could play a crucial role. Vamstar, with its advanced digital procurement solutions, can support the adoption of these recommendations by providing a more efficient, transparent, and data-driven approach to procurement. Its technology could facilitate better collaboration among stakeholders, streamline the procurement process, and offer insights into market trends and supplier performance.

This aligns perfectly with EFPIA’s call for improved procedures and increased transparency in the tendering process. By leveraging such innovative platforms, stakeholders can work together more effectively to ensure a healthcare system that not only meets the needs of its patients but also aligns with the resilience and growth goals of the EU.

Background

The House of Commons Committee on Public Accounts released a report on March 20th, 2024, addressing the inefficiencies in the NHS Supply Chain procurement processes.

The report shed light on various challenges, including difficulties in achieving market share targets, oversight problems, lack of trust among stakeholders, and delayed transformation initiatives.

In this article, we explore the context of the report and propose recommendations for implementing an AI-based data orchestration platform to foster consistency, trust, and transparency in the procurement processes.

Introduction

The NHS spends approximately £8 billion annually on medical equipment and consumables. NHS Supply Chain, established in 2018, aims to deliver savings and increase market share by aggregating spending power and reducing price variations.

However, challenges persist in persuading trusts to utilise the NHS Supply Chain, resulting in missed savings opportunities. This paper explores how AI-based data orchestration systems can address these challenges and improve NHS Supply Chain’s efficiency and patient outcomes.

Key Challenges

1. Low Trust Participation: NHS Supply Chain has failed to persuade trusts to use its services, resulting in only 57% market share against a target of 80% by 2023-24. This limits potential savings and efficiency gains.
2. Weak Oversight and Support: NHSE has been weak in its oversight and support of NHS Supply Chain, failing to validate claimed savings and provide adequate financial support for modernization efforts.
3. Lack of Trust Accountability: NHSE does not effectively challenge trusts to purchase more through the NHS Supply Chain, relying on trusts to analyse procurement data and change practices independently.
4. Inconsistent Savings Reporting: NHS Supply Chain has used multiple methods to calculate and report savings, causing confusion and mistrust among trusts.
5. Delayed Transformation Benefits: NHS Supply Chain’s transformation program, aimed at improving its business, is expected to run from 2022-30. Benefits will take several years to materialise due to capacity constraints and legacy system challenges.
6. Balancing Cost and Quality: There are concerns that a focus on costs may impact product quality and patient outcomes. Clinicians need to be more involved in purchasing choices to ensure patient care is considered alongside value and cost.

To address these challenges and enhance the efficiency of the NHS Supply Chain, we propose the implementation of an AI-driven data orchestration technology and analytics to reduce risk to the NHS. This technology will ensure data consistency, build trust, and promote transparency in the procurement processes.

AI-based Data Orchestration Solution will support

1. Predictive Demand Forecasting: Implement AI algorithms to analyse historical procurement data, patient demographics, and clinical trends to accurately forecast demand for medical equipment and consumables. This will enable NHS Supply Chain to optimise inventory levels, reduce stockouts, and improve trust participation by ensuring product availability.
2. Dynamic Pricing Optimisation: Develop an AI-powered pricing engine that continuously analyses market conditions, supplier contracts, and trust purchasing patterns to offer competitive and transparent prices. This builds trust and confidence, and encourages increased utilisation of the NHS Supply Chain.
3. Intelligent Procurement Analytics: Deploy AI-driven analytics to identify purchasing patterns, price variations, and potential savings opportunities across trusts. Provide actionable insights to NHSE and trusts, enabling data-driven challenges and accountability for utilising NHS Supply Chain.
4. Unified Savings Reporting: Establish a standardised, AI-powered savings calculation methodology that integrates data from NHS Supply Chain, trusts, and suppliers. Ensure consistency, transparency, and trust in reported savings across all stakeholders.
5. AI-assisted Transformation Management: Leverage AI project management tools to optimise resource allocation, identify critical paths, and monitor progress of NHS Supply Chain’s transformation program. Use predictive analytics to anticipate and mitigate risks, ensuring timely delivery of modernisation benefits.
6. Value-based Procurement: Implement an AI framework that incorporates clinical outcomes, patient satisfaction, and long-term cost savings into procurement decisions. Engage clinicians in defining value metrics and utilise AI to analyse real-world evidence, ensuring a balance between cost and quality.

Conclusion

Implementing AI-based data orchestration systems can significantly enhance NHS Supply Chain’s efficiency, savings, and patient outcomes. By leveraging predictive analytics, dynamic pricing, intelligent procurement insights, unified savings reporting, AI-assisted transformation management, and value-based procurement, NHS Supply Chain can overcome existing challenges and drive trust participation. Collaboration among NHS Supply Chain, NHSE, trusts, and clinicians is crucial to realise the full potential of these AI solutions and ensure a sustainable, patient-centric procurement process.

Challenges and Opportunities in Sustainable Procurement

Challenges

While the shift towards sustainable procurement in healthcare is promising, it’s not without its challenges. One major hurdle is the initial cost. Often, sustainable products and solutions come with a higher price tag compared to conventional alternatives. This can be a significant barrier, especially in regions with constrained healthcare budgets.

Another challenge lies in the availability and accessibility of sustainable options. The market for ethically produced and environmentally friendly products is still evolving. Healthcare providers may find it difficult to source products that meet both their sustainability criteria and medical standards.

Strategic Procurement in Healthcare

Strategic procurement in the healthcare sector goes beyond the traditional focus on cost efficiency and quality. It embodies a broader vision, integrating ethical sourcing, environmental sustainability, and societal well-being into purchasing decisions. This shift is not merely about selecting products and services; it’s about aligning procurement practices with the values of health and sustainability.

The concept intertwines with the core mission of healthcare – to promote and protect health. By prioritising ethically produced and sustainable products, healthcare providers can influence the market, encouraging manufacturers to adopt greener and more socially responsible practices. This approach is especially significant given the healthcare sector’s substantial purchasing power within the EU.

Case Studies of Sustainable Procurement in EU Healthcare

Circular Procurement in Danish Healthcare

In Denmark, the healthcare sector is pioneering circular procurement, an approach that emphasises the reuse and recycling of products. This strategy not only reduces waste but also ensures that products have a longer life cycle, aligning with sustainability goals. For instance, Danish hospitals are increasingly opting for medical equipment and supplies that offer environmentally friendly disposal options or can be recycled, thus reducing their carbon footprint.

Pre-Commercial Procurement in Catalonia

Catalonia is taking a different but equally innovative approach by implementing Pre-Commercial Procurement (PCP) procedures. These procedures are designed to address societal challenges such as antimicrobial resistance (AMR). By focusing on pre-commercial stages, Catalonia is encouraging the development of cutting-edge solutions that are not only sustainable but also address critical health challenges. This forward-thinking approach positions the region at the forefront of healthcare innovation and sustainability.

Other EU Initiatives

Across the EU, various regions are adopting similar strategies. These include efforts to source locally, thereby reducing transportation emissions, and prioritising products with a lower environmental impact. Such diversity in approaches highlights the versatility of strategic procurement and its adaptability to different regional needs and challenges.

Introduction

The European healthcare sector, a vital component of the continent’s economy, contributes approximately 14% to the European Union’s annual Gross Domestic Product (GDP). This significant financial influence is not just a testament to its economic importance, but also a potent leverage point for broader societal impacts. In recent years, there has been a growing emphasis on leveraging this influence to promote sustainability. This approach, known as strategic procurement, is increasingly being recognised for its potential to drive ethical, healthy, and environmentally sustainable practices within the sector.

Opportunities

Despite these challenges, sustainable procurement in healthcare also presents significant opportunities. Firstly, it opens the door to innovation. As the demand for sustainable products increases, manufacturers are incentivised to invest in research and development, leading to new, more sustainable technologies and products.

Secondly, it creates the potential for long-term cost savings. While the initial investment might be higher, sustainable products often have lower lifecycle costs due to factors like energy efficiency and durability.

Lastly, sustainable procurement aligns healthcare practices with broader societal values, enhancing public trust and reputation. It also contributes significantly to public health by reducing environmental impact, thus indirectly improving health outcomes.

Conclusion

The strategic procurement initiatives in the European healthcare sector reflect a profound shift towards sustainability and ethical responsibility. From Denmark’s circular procurement to Catalonia’s innovative Pre-Commercial Procurement, these strategies demonstrate a commitment to not just healthcare in the traditional sense, but to the health of the planet and society as a whole.

As the sector continues to navigate the challenges, the opportunities for positive change and innovation are immense. The move towards sustainable procurement is more than a trend; it’s a necessary evolution in response to global environmental and social challenges. It highlights the unique role that the healthcare sector can play in leading the way towards a more sustainable future.

The journey towards fully sustainable procurement is ongoing, but the steps taken by the European healthcare sector are significant. They serve as a beacon, showing that strategic procurement can be a powerful tool in aligning economic activities with ethical and environmental values, ultimately contributing to a healthier world for all.